Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Boston Scientific Becomes Third US TAVR Competitor With Lotus Edge Approval

Apr 24 2019

• By Reed Miller

New competition business concept with a chess pawn punching and destroying competitors as two king pieces with hidden red boxing gloves as a metaphor for innovative corporate attack strategy. - Illustration — • Source: shutterstock.com

Related Content

EuroPCR 2017: Boston Scientific's Lotus TAVR Beats Medtronic's CoreValve In REPRISE III, But Pacemaker Issue Remains

May 16 2017

Transcatheter Systems Set To Dominate Heart Valve Market

Oct 30 2017

Symetis TAVR Buy Not About Throwing Shade On Lotus, BSX Insists

Mar 30 2017

Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump

Jan 29 2019

ACC Results Recap Part I: Low-Risk TAVR Trials Bring Good News For Edwards And Medtronic; Apple Watch Detects AFib In Apple Heart Study

Mar 19 2019

Boston Scientific Pulls All Lotus TAVR Systems Off Shelves

Feb 23 2017

Three Devices Gain Medicare Add-Ons, Including Boston Sci's New TAVR Protector

Aug 03 2018

EuroPCR 2018: Real-World TAVR Data Show Consistent Performance With Edwards, Abbott, And Medtronic's Systems

May 23 2018

Related Companies

Boston Scientific Corporation

Edwards Lifesciences Corp.

Abbott

Additional Topics

Approvals Innovation FDA Research & Development Cardiovascular Medical Device

More from Approvals

More from Policy & Regulation

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window